Wedbush Reiterates Outperform on Monte Rosa Therapeutics, Maintains $11 Price Target
Portfolio Pulse from Benzinga Newsdesk
Wedbush analyst Robert Driscoll has reiterated an Outperform rating on Monte Rosa Therapeutics (NASDAQ:GLUE) and maintained a price target of $11.
May 22, 2024 | 2:54 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Wedbush analyst Robert Driscoll has reiterated an Outperform rating on Monte Rosa Therapeutics and maintained a price target of $11.
The reiteration of an Outperform rating and the maintenance of a price target at $11 by a reputable analyst can boost investor confidence in Monte Rosa Therapeutics, potentially leading to a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100